![]() |
Trials |
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological MalignanciesCancer type: Hematological malignancies Phase: I Principal Investigator: Mau-Sørensen Morten Country: DK Keywords: Denmark, Rigshospitalet,selective inhibitor of nuclear expert, CRM-1, hematological malignancies Status: Completed Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01607892 |